US 12,129,494 B2
T7 RNA polymerase variants
Mathew G. Miller, San Carlos, CA (US); Chinping Chng, Menlo Park, CA (US); Oscar Alvizo, Fremont, CA (US); Melissa Ann Mayo, Foster City, CA (US); James Nicholas Riggins, San Francisco, CA (US); Xiang Yi, San Carlos, CA (US); Jonathan S. Penfield, Truckee, CA (US); Gjalt W. Huisman, Redwood City, CA (US); Jared Davis, Cheshire, CT (US); and Yasushi Saotome, Solana Beach, CA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Dec. 21, 2021, as Appl. No. 17/558,454.
Application 16/938,793 is a division of application No. 16/012,462, filed on Jun. 19, 2018, granted, now 10,738,286, issued on Aug. 11, 2020.
Application 17/558,454 is a continuation of application No. 16/938,793, filed on Jul. 24, 2020, granted, now 11,236,311.
Claims priority of provisional application 62/528,840, filed on Jul. 5, 2017.
Claims priority of provisional application 62/527,740, filed on Jun. 30, 2017.
Prior Publication US 2022/0186197 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/12 (2006.01); C12P 19/34 (2006.01); C12N 15/00 (2006.01)
CPC C12N 9/1247 (2013.01) [C12P 19/34 (2013.01); C12Y 207/07006 (2013.01); C12N 15/00 (2013.01)] 17 Claims
 
1. An engineered RNA polymerase having a polypeptide sequence comprising at least 95% sequence identity to SEQ ID NO: 4 or 15, wherein the polypeptide sequence comprises at least a substitution at position 514, wherein the position is relative to SEQ ID NO: 4 or 15.